Results 61 to 70 of about 45,216 (237)

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis

Frontiers in Pharmacology, 2022
Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu, Zhi-Yong Liu, Dan-Ying Zhang, Dan-Ying Zhang, Xia-Hui Lin, Xia-Hui Lin, Jia-Lei Sun, Jia-Lei Sun, Weinire Abuduwaili, Weinire Abuduwaili, Guang-Cong Zhang, Guang-Cong Zhang, Ru-Chen Xu, Ru-Chen Xu, Fu Wang, Fu Wang, Xiang-Nan Yu, Xiang-Nan Yu, Xuan Shi, Xuan Shi, Bin Deng, Ling Dong, Ling Dong, Shu-Qiang Weng, Shu-Qiang Weng, Ji-Min Zhu, Ji-Min Zhu, Xi-Zhong Shen, Xi-Zhong Shen, Xi-Zhong Shen, Tao-Tao Liu, Tao-Tao Liu   +31 more
doaj   +1 more source

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]

, 2015
Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W, Faltermeier, Claire, Zarrinpar, Ali   +2 more
core   +2 more sources

Cell Viability, Drug Screening, and Mechanism Study Under Mild Phototherapy Integrated Chemotherapy (PIC)

Advanced Science, EarlyView.
Mild phototherapy integrated chemotherapy (mild‐PIC) monitored by real‐time impedance spectroscopy enhances drug efficacy in liver cancer via the “More Light‐Aiding, Less Bonding (LALB)” mechanism, achieving higher targeting with lower toxicity. Abstract Phototherapy integrated chemotherapy (PIC) offers a promising cancer treatment strategy as single ...
Tongge Li, Shihui Wang, Qianhui Ling, Junyi Sun, Ning Yang, Zhanglei Fu, Zhaoyuan Zhang, Si Chen, Yanfei Wang, Ni Yu, Yafei Wang, Zhexuan Ding, Haodong Liu, Yanwei Jia, Yifang Wang, Xingcai Zhang   +15 more
wiley   +1 more source

Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma

Journal of Translational Medicine
Background Sorafenib resistance is becoming increasingly common and disadvantageous for hepatocellular carcinoma (HCC) treatment. Ferroptosis is an iron dependent programmed cell death underlying the mechanism of sorafenib.
Xiuya Hu, Peiyu Zhang, Sai Li, Jiaqi Zhang, Danni Wang, Zihan Wang, Lu Zhu, Lingdi Wang   +7 more
doaj   +1 more source

HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters

International Journal of Genomics, 2022
Hepatocellular carcinoma (HCC) represents a common malignancy, and mechanisms of acquired sorafenib resistance during the treatment of HCC patients remain elusive.
Xian Zhu, Yinfang Zhang, Yafei Wu, Wenjing Diao, Guilong Deng, Qin Li, Chuanxing Wu   +6 more
doaj   +1 more source

m6A‐Modified circRAPGEF1 Interaction with IGF2BP3 Promotes Hepatocellular Carcinoma Progression via Reprogramming Aspartate Metabolism

Advanced Science, EarlyView.
In hepatocellular carcinoma (HCC), the m6A‐modified circRAPGEF1 destabilizes ASS1 mRNA via competitive binding to IGF2BP3, driving aspartate metabolic reprogramming in liver cancer stem cells (LCSCs). This cascade enhances stemness properties and reduces sorafenib sensitivity in LCSCs, thereby identifying circRAPGEF1 as a promising therapeutic target ...
Juanyi Shi, Sintim Mui, Yongcong Yan, Shaomin Liu, Kai Wen, Chuanchao He, Huoming Li, Hao Liao, Meng Tao, Jiahua Wen, Weidong Wang, Xiaoding Xu, Zhenyu Zhou, Zhiyu Xiao   +13 more
wiley   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Clathrin Light Chain B Drives Hepatocellular Carcinoma Progression Through Dual Mechanisms: Small Extracellular Vesicle‐Mediated Angiogenesis and the NF‐κB–PCLAF Signaling Axis

Advanced Science, EarlyView.
Clathrin Light Chain B (CLTB) drives hepatocellular carcinoma progression through dual pathways: intracellularly, it activates the NF‐κB–PCLAF axis to enhance small extracellular vesicle (sEV) uptake and tumor proliferation; extracellularly, CLTB‐enriched sEVs bind SH3KBP1 to inhibit its degradation, inducing angiogenesis and vascular leakage ...
Xiaoke Sun, Junchen Guo, Ning Zhao, Guanghua Cui, Yun Bai, Meijuan Ding, Yi Xu, Yu Yang   +7 more
wiley   +1 more source

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma

Frontiers in Oncology, 2023
Hepatocellular carcinoma (HCC) is a heterogeneous and aggressive liver cancer that presents limited treatment options. Despite being the standard therapy for advanced HCC, sorafenib frequently encounters resistance, emphasizing the need to uncover the ...
Siqi Chen, Siqi Chen, Siqi Chen, Yaqing Du, Xin-Yuan Guan, Qian Yan, Qian Yan, Qian Yan   +7 more
doaj   +1 more source

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. [PDF]

, 2017
Aberrant cytokine signaling initiated from mutant receptor tyrosine kinases (RTKs) provides critical growth and survival signals in high risk acute myeloid leukemia (AML).
Arbiser, Jack L, Bradley, Heath L, Bunting, Kevin D, Kapur, Reuben, Metts, Jonathan, Shah, Neil P, Wang, Zhengqi   +6 more
core   +1 more source